{"nctId":"NCT03096847","briefTitle":"Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer","startDateStruct":{"date":"2016-10-24","type":"ACTUAL"},"conditions":["Advanced Metastatic Breast Cancer"],"count":502,"armGroups":[{"label":"ribociclib + letrozole cohort A","type":"EXPERIMENTAL","interventionNames":["Drug: ribociclib","Drug: letrozole","Drug: goserelin"]},{"label":"ribociclib + letrozole cohort B1","type":"EXPERIMENTAL","interventionNames":["Drug: ribociclib","Drug: letrozole","Drug: goserelin"]},{"label":"ribociclib + letrozole cohort B2","type":"EXPERIMENTAL","interventionNames":["Drug: ribociclib","Drug: letrozole","Drug: goserelin"]}],"interventions":[{"name":"ribociclib","otherNames":["LEE011"]},{"name":"letrozole","otherNames":[]},{"name":"goserelin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient is an adult, ≥ 18 years old at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines\n* Women and men with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.\n* Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive and HER2-negative breast cancer by local laboratory. Local pathology is sufficient for assessment.\n* Patient must have either:\n\n  1. Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria ).\n  2. Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease\n  3. Non-measurable disease\n* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n\nExclusion Criteria\n\n* Patient who received any CDK4/6 inhibitor or any mTOR inhibitor.\n* Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole\n* Patients with current inflammatory breast cancer.\n* Patient has received \\> 1 chemotherapy for the treatment of advanced/metastatic breast cancer\n* Patient has received \\> 2 endocrine therapies for the treatment of advanced/metastatic breast cancer\n* Patient has central nervous system (CNS) involvement. If patient is fulfilling the following 3 criteria she/he is eligible for the trial.\n\n  1. completed prior therapy (including radiation and/or surgery) for CNS metastases ≥ 28 days prior to the start of study and\n  2. CNS tumor is clinically stable at the time of screening and\n  3. Patient is not receiving steroids and enzyme inducing anti-epileptic medications for brain metastases\n* Patient has active cardiac disease or a history of cardiac dysfunction","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole","description":"Clinical Benefit Rate (CBR) after 24 weeks of treatment as defined by RECIST 1.1 as percentage of patients with Complete Response (CR), Partial response (PR) or Stable disease (SD) lasting 24 weeks or longer as well as patients with Non-complete response, nonprogressive disease (NCRNPD).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"57.7","spread":null},{"groupId":"OG002","value":"56.5","spread":null},{"groupId":"OG003","value":"60.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":null},{"groupId":"OG001","value":"69.2","spread":null},{"groupId":"OG002","value":"64.3","spread":null},{"groupId":"OG003","value":"69.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) for Different Populations - Kaplan-Meier Estimates (%, 95% CI)","description":"PFS based on radiologic assessment by investigator using RECIST 1.1 criteria","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"67.0","spread":null},{"groupId":"OG002","value":"63.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"58.7","spread":null},{"groupId":"OG002","value":"47.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"49.6","spread":null},{"groupId":"OG002","value":"39.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) for Different Populations - Median Time to Progression or Death With 95% CI [Months]","description":"PFS based on radiologic assessment by investigator using RECIST 1.1 criteria","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null},{"groupId":"OG001","value":"16.5","spread":null},{"groupId":"OG002","value":"8.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Kaplan-Meier Estimates (%, 95% CI)","description":"Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause. For the Kaplan-Meier estimates (%, 95% CI), the probability of survival at week 24, 48 and 72 is reported below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"81.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Median Time to Progression or Death With 95% CI [Months]","description":"Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Number of Censored Participants and Number of Deaths","description":"Overall survival (OS) defined as the time from date of start of treatment to date of death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) - Kaplan-Meier Estimates (%, 95% CI)","description":"Overall response rate (ORR) is the best overall response (BOR) of complete response (CR) or partial response (PR) as defined by RECIST 1.1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"23.1","spread":null},{"groupId":"OG002","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"30.8","spread":null},{"groupId":"OG002","value":"16.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 24 of Patient Reported Quality of Life (QoL) Via EORTC QLQ-C30","description":"The QLQ-C30 is the core questionnaire of the EORTC QLQ, which has been developed for the assessment of the health-related QOL of cancer patients participating in international clinical trials. Using a linear transformation to standardize the raw scores, all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (\"better\") level of functioning (applies to the first 6 items, items 1 to 6), but a higher (\"worse\") level of symptoms (applies to the last 9 items, items 7 to 15). There is no aggregated total score, i.e., all scale scores were analyzed separately.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"23.7"},{"groupId":"OG001","value":"11.7","spread":"20.8"},{"groupId":"OG002","value":"5.0","spread":"26.2"},{"groupId":"OG003","value":"6.1","spread":"25.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"19.9"},{"groupId":"OG001","value":"-3.6","spread":"10.7"},{"groupId":"OG002","value":"-2.2","spread":"17.7"},{"groupId":"OG003","value":"-2.4","spread":"16.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"31.9"},{"groupId":"OG001","value":"-17","spread":"21.8"},{"groupId":"OG002","value":"-1.3","spread":"34.7"},{"groupId":"OG003","value":"-3.9","spread":"33.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"24.2"},{"groupId":"OG001","value":"-9.4","spread":"25.0"},{"groupId":"OG002","value":"-3.6","spread":"21.8"},{"groupId":"OG003","value":"-4.6","spread":"22.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"23.7"},{"groupId":"OG001","value":"2.2","spread":"28.1"},{"groupId":"OG002","value":"1.1","spread":"21.6"},{"groupId":"OG003","value":"1.3","spread":"22.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"27.9"},{"groupId":"OG001","value":"-16","spread":"21.3"},{"groupId":"OG002","value":"-5.3","spread":"31.3"},{"groupId":"OG003","value":"-7.0","spread":"30.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"25.9"},{"groupId":"OG001","value":"11.1","spread":"20.6"},{"groupId":"OG002","value":"3.9","spread":"27.1"},{"groupId":"OG003","value":"5.1","spread":"26.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"16.7"},{"groupId":"OG001","value":"1.1","spread":"22.2"},{"groupId":"OG002","value":"-4.9","spread":"19.1"},{"groupId":"OG003","value":"-3.9","spread":"19.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"31.9"},{"groupId":"OG001","value":"15.6","spread":"24.8"},{"groupId":"OG002","value":"9.0","spread":"27.6"},{"groupId":"OG003","value":"10.1","spread":"27.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"32.4"},{"groupId":"OG001","value":"4.4","spread":"21.3"},{"groupId":"OG002","value":"-5.3","spread":"30.5"},{"groupId":"OG003","value":"-3.7","spread":"29.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"33.2"},{"groupId":"OG001","value":"6.7","spread":"31.4"},{"groupId":"OG002","value":"4.9","spread":"32.7"},{"groupId":"OG003","value":"5.2","spread":"32.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"33.7"},{"groupId":"OG001","value":"6.7","spread":"28.7"},{"groupId":"OG002","value":"1.4","spread":"30.9"},{"groupId":"OG003","value":"2.2","spread":"30.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"26.6"},{"groupId":"OG001","value":"2.2","spread":"26.6"},{"groupId":"OG002","value":"-3.6","spread":"27.9"},{"groupId":"OG003","value":"-2.6","spread":"27.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"24.6"},{"groupId":"OG001","value":"0.0","spread":"45.4"},{"groupId":"OG002","value":"2.3","spread":"27.2"},{"groupId":"OG003","value":"1.9","spread":"30.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"27.7"},{"groupId":"OG001","value":"-4.4","spread":"24.8"},{"groupId":"OG002","value":"-1.4","spread":"25.1"},{"groupId":"OG003","value":"-1.9","spread":"24.9"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Quality of Life (QoL) Via EORTC BR-23 - Change From Baseline at Week 24 (Cycle 7)","description":"To evaluate health related quality of life (QoL) via EORTC BR-23. The scoring approach for the QLQ-BR23 is identical in principle to that for the function and symptom scales / single items of the QLQ-C30, i.e., all scores finally range from 0 to 100, where a higher score represents a higher response level, e.g., a higher (\"better\") level of functioning, (applies to the first 4 items, items 1 to 4) but a higher (\"worse\") level of symptoms (applies to the last 4 items, items 5 to 8).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"18.2"},{"groupId":"OG001","value":"-0.6","spread":"22.2"},{"groupId":"OG002","value":"0.4","spread":"22.7"},{"groupId":"OG003","value":"0.2","spread":"22.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"17.7"},{"groupId":"OG001","value":"0.0","spread":"24.5"},{"groupId":"OG002","value":"0.8","spread":"18.0"},{"groupId":"OG003","value":"0.7","spread":"19.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"31.3"},{"groupId":"OG001","value":"-17","spread":"23.6"},{"groupId":"OG002","value":"7.4","spread":"26.9"},{"groupId":"OG003","value":"5.0","spread":"27.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20","spread":"33.4"},{"groupId":"OG001","value":"-24","spread":"26.6"},{"groupId":"OG002","value":"-12","spread":"26.2"},{"groupId":"OG003","value":"-14","spread":"26.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"16.6"},{"groupId":"OG001","value":"-13","spread":"22.3"},{"groupId":"OG002","value":"-6.0","spread":"14.9"},{"groupId":"OG003","value":"-7.1","spread":"16.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"15.7"},{"groupId":"OG001","value":"8.3","spread":"22.7"},{"groupId":"OG002","value":"0.9","spread":"17.5"},{"groupId":"OG003","value":"2.2","spread":"18.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"21.1"},{"groupId":"OG001","value":"-1.5","spread":"22.6"},{"groupId":"OG002","value":"-2.1","spread":"18.1"},{"groupId":"OG003","value":"-2.0","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22","spread":"43.4"},{"groupId":"OG001","value":"-17","spread":"23.6"},{"groupId":"OG002","value":"-14","spread":"33.9"},{"groupId":"OG003","value":"-15","spread":"32.1"}]}]}]},{"type":"SECONDARY","title":"Time to 10% Deterioration in EORTC Global Health Status","description":"Time to 10% deterioration in the European Organisation for Research and Treatment of Cancer (EORTC) global health status","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"3.7","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAE)","description":"Adverse Events (AEs) were separated into TEAEs (defined as AEs occurring/worsening from first study drug treatment until 30 days after the last study drug treatment) and AEs in the pre-/post-treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"317","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"302","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 1150 days (approx 3.15 years). (Treatment duration ranged from 2 days to 1120 days). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 3.15 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"136","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":97,"n":319},"commonTop":["NEUTROPENIA","NAUSEA","FATIGUE","ALOPECIA","NASOPHARYNGITIS"]}}}